Jeremy Cohen’s Post

Thrilled to share the launch of Spinnaker Life Sciences Strategy Consulting! Brooks Hill Partners, Red Team Associates, and Solstice Strategy Group have joined forces to form Spinnaker Life Sciences Strategy Consulting with offices located in Boston and Minneapolis. The merger marks a strategic alliance that combines the strengths, expertise, and innovative approaches of three industry leaders to help pharmaceutical, biotech, and med-tech companies navigate smarter strategies during the current challenging capital and commercialization life sciences environment. Looking forward to seeing what's to come! Learn more at www.spinnakerLS.com #healthcareconsulting #lifesciences #consulting #strategyconsulting #healthcare #pharmaceutical #biotechnology #medicaldevices #venturecapital #vc #vcfunding #startup #fundraising #digitalhealth #healthtech #healthcareindustry #partnerships #healthcarerecruiting #latestnews #healthcarecareer

Interesting observations from my colleague Jayshree Shah on how dealmakers and investors navigate the fast moving opportunities as AI and technology in general impact LSHC. Interpath Deal Advisory team are well placed to support companies and investors unlock and maximise value through the corporate lifecycle #mna #deals #lifescience #healthcaremna

#Partnerships with external investors like Tesi are crucial for BC Platforms' growth and internationalization. 🚀 #data #drugdevelopment #healthcare #precisionmedicine #healthtech #healthtechinnovation

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

Being a partner of choice is about building creative, tailored deals to accelerate the development of innovative therapies that can extend and improve patients’ lives. Bradley Hardiman, Senior Director, Astellas Venture Management spoke with Pharma Intelligence, now Citeline to discuss the ever-evolving biopharma dealmaking landscape, challenges within the industry and his hopes for 2024. Read the full article here:  https://bit.ly/3Nm4q2A  *You may need to subscribe to read it. #ScienceFirstForPatients #ChangingTomorrow

🔥💡 Investors Whisper to Pharma: What's Your Next Big Move? 💡🔥 2024 started with a buzz! $6.4B in health-care deals kick-started at the JPMorgan Healthcare Conference announced on January 8. From Merck & Co.'s strategic $680 million acquisition of Harpoon Therapeutics to Boston Scientific's bold $3.7 billion move on Axonics, and J&J's forward-thinking $2 billion purchase of Ambrx Biopharma, the message is clear: 🚀 The future is now, and it's driven by innovation. 🚀 👀 But let's have a closer look at the Market's Signals: Mixed! Acquirers steady 🛡️, Targets skyrocket 🚀 Harpoon & Ambrx: Shares ⬆️ over 100% Axonics: Shares ⬆️ 21% 🤔 So what is the Investors' Message? They value potential over present! 🌈 Pharma need to Transform Promise into Performance 🚀 ✨ Investors now know that it's difficult for Pharma companies to go beyond their operational model and just integrate these new assets to create value.   To gain back credit from the market, Pharma companies must leap forward in how they integrate, develop, and bring these innovations to market. And at the heart of this challenge? The supply chain. why? As investors place a premium on potential, they implicitly underscore the critical role of supply chain management in unlocking that value. A robust, agile, and efficient supply chain isn't just an operational necessity; it's a strategic asset, a key to transforming promising acquisitions into real-world solutions that can sustain and accelerate growth. 💥 🔄 So, what’s the take-home message for pharma leaders? It's that in this new era, the spotlight isn't just on what you acquire; it's on how you bring that acquisition to life through superior supply chain capabilities. A call to action to evolve supply chains from back-end operations to strategic enablers. 💡 As we navigate this new landscape, the spotlight turns to us. Let's discuss! 🔗 (Fortune article in the comment) #PharmaTrends #InvestorInsights #SupplyChainInnovation #HealthcareDeals

As part of SELLAS Life Sciences Group, Inc. ongoing commitment to fiscal responsibility and efficiency, we have made the difficult but necessary decision to further streamline our operations and optimize our resources to achieve long-term success. By making these changes, we are taking bold steps towards becoming an even leaner organization and prioritizing our efforts and allocating resources strategically towards the success of our clinical programs and focus on commercialization partnerships. 2024 should be a transformational year for our two promising assets, galinpepimut-S (GPS) and our highly selective CDK9 inhibitor, SLS009. As I mentioned on the January shareholder call, we are implementing initiatives to not only remain well capitalized as we expect key data read-outs in REGAL and SLS009 this year, but we will are also further adjusting and refining our internal resources - these strategic initiatives, combined with our strong clinical data and commitment to maximizing shareholder value, will position us for long-term success and I am committed, the entire SELLAS team is committed, to delivering positive outcomes for our shareholders. https://lnkd.in/eCkRGU-r

SBVA, led by CEO Lee Jun-pyo, has announced its leadership in the pre-IPO funding round for Baropharm, a comprehensive pharmacy management platform. This round attracted new investor KDB Capital, alongside existing backers Mirae Asset Capital, Mirae Asset Venture Investment, and Company K Partners, totaling an impressive ₩15 billion ($11 million) in investments. Baropharm's cumulative funding has now reached ₩35 billion ($26 million) as it prepares for its IPO, having appointed Mirae Asset Securities as its lead manager in March. Founded in July 2021 by practicing pharmacists Kim Seul-ki and Shin Kyung-do, Baropharm has rapidly grown, now serving over 20,000 pharmacies—80% of the national market—and achieving a cumulative order volume of ₩3 trillion. The platform enhances pharmacy operations by providing integrated pharmaceutical ordering, restocking alerts for out-of-stock items, returns management, and community features, significantly improving customer convenience. Jung Ji-woo, Executive Director of SBVA, remarked, "Since its inception, Baropharm has swiftly attracted customers and proven the competitiveness of its pharmaceutical ordering platform through remarkable growth. We look forward to future expansions into health management commerce and a range of B2B services leveraging data." Kim Seul-ki emphasized that this investment marks a pivotal step in accelerating Baropharm's growth and building a robust ecosystem as a pharmaceutical platform through innovative solutions. Source: ZDNET #PharmacyManagement #PreIPO #StartupInvestment #HealthcareInnovation #KoreanStartups #KoreaBusiness

What’s next for Doliprane? Sanofi's consumer health unit, home to the iconic Doliprane, is stirring up a bidding frenzy ! Two heavyweight contenders have stepped into the ring for a potential $17 billion deal : Clayton Dubilier & Rice and PAI Partners (with an all-star lineup of co-investors). PAI Partners isn't playing solo. They've assembled a team: Abu Dhabi Investment Authority (ADIA), Singapore's GIC, British Columbia Investment. Sanofi's potential divestiture aligns with their laser-focused strategy of streamlining operations. But here's the kicker : if successful, the winning bidder will snag a whopping 50% stake in Doliprane's parent unit. No decision has been inked yet. If the bids don't hit the sweet spot, Sanofi might pivot to a spinoff strategy. An intriguing deal to follow :)

💡 NAVIGATING RISK AVERSION IN LARGE PHARMA: INSIGHTS FROM A CBO As I gather insights for my upcoming report on Chief Business Officer challenges, another recurring theme has emerged: risk aversion in large pharmaceutical companies. In a recent conversation, a CBO from a clinical-stage, US-based biotech shared his experience: "When you're sitting in one of those corporate development roles in a large biopharma, you're not incentivized to say yes, because most of the time things won't work. Nobody wants to be remembered as the person who spent money on something that didn’t succeed." This creates a bias toward saying “no” to early-stage deals, even though larger companies could benefit from making multiple small bets. The idea of having “more shots on goal” (making many smaller investments to increase the chance of success) often loses out to the trend toward fewer, larger acquisitions. 🔑 The solution? Building internal champions. The CBO emphasized that for early-stage biotech companies, success often depends on finding internal scientific or technical champions within big pharma. Corporate development teams alone can’t push these deals through—internal champions help navigate internal processes and bring key stakeholders to the table. For small biotech companies, proactively identifying and nurturing relationships with these champions is key to unlocking potential partnerships. How are you navigating risk aversion when approaching large pharma for partnerships? Let’s share strategies that have worked in this challenging landscape. #Biotech #BusinessDevelopment #CBOChallenges #Partnering